StreetInsider.com News Articles

More than 175 biotechs adopt Veeva Basics for drug development ops

Wed, 07 Oct 2026 07:05:42 -0400

Veeva Systems (NYSE: VEEV) announced that more than 175 emerging biotechnology companies have adopted its Veeva Basics platform, a suite of pre-configured and pre-validated applications covering clinical, regulatory, quality, medical, and commercial functions.

According to the company's press release, biotechs are deploying the applications within weeks, with the platform built to scale as companies grow from startup to commercialization. The applications run on Veeva's Vault Platform.

One feature highlighted in the announcement is Veeva Submissions Publishing Basics, which allows regulatory teams to bring submission publishing in-house rather than relying on outside vendors. The tool is aimed at companies preparing to file their

More than 175 biotechs adopt Veeva Basics for drug development ops

Wed, 07 Oct 2026 07:05:42 -0400

Emerging Biotechs Standardize on Veeva Basics to Accelerate Drug Development

Wed, 07 Oct 2026 07:03:00 -0400

More than 175 biotechs use pre-configured applications to streamline operations

PLEASANTON, Calif., Oct. 7, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that more than 175 emerging biotechs are establishing a technology foundation with Veeva Basics. Biotechs are launching pre-configured and pre-validated Veeva Basics applications in weeks, adding systems that can

Emerging Biotechs Standardize on Veeva Basics to Accelerate Drug Development

Wed, 07 Oct 2026 07:03:00 -0400

More than 175 biotechs use pre-configured applications to streamline operations

Emerging Biotechs Standardize on Veeva Basics to Accelerate Drug Development

Wed, 07 Oct 2026 07:03:00 -0400

More than 175 biotechs use pre-configured applications to streamline operations

Emerging Biotechs Standardize on Veeva Basics to Accelerate Drug Development

Wed, 07 Oct 2026 07:03:00 -0400

More than 175 biotechs use pre-configured applications to streamline operations

Form 4 Structure Therapeutics For: Sep 18 Filed by: Coll Crespo Blas

Tue, 22 Sep 2026 18:00:00 -0400

si-local-file:///var/storage/secattach/20260922/27092062.html

Form 144 Structure Therapeutics Filed by: Coll Crespo Blas

Mon, 21 Sep 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260921/27085755.html

H.C. Wainwright Reiterates Buy Rating on Structure Therapeutics (GPCR)

Wed, 09 Sep 2026 07:26:54 -0400

H.C. Wainwright analyst Ananda Ghosh reiterated a Buy rating and $70.00 price target on Structure Therapeutics (NASDAQ: GPCR).

The analyst commented: "For aleniglipron, the ACCESS OLE showed 16.2% weight loss at 72 weeks with no plateau in the top dose, achieved on roughly 7.3 weeks of median 180 mg exposure, and AE discontinuations of 2.6% on the 2.5 mg start dose that Phase 3 uses, all supporting our best-in-class, commercially viable thesis, in our opinion. We think step-size design along with the starting dose drove the tolerability improvement, which in our view answers the titration debate. As for the amylin program,

Structure Therapeutics (GPCR) Reiterated at Market Outperform by Citizens

Wed, 09 Sep 2026 04:24:32 -0400

Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $110.00 price target on Structure Therapeutics (NASDAQ: GPCR).

The analyst commented, "Structure’s small molecule engine is humming with durable and clean 72-week follow-up for aleniglipron and the first-in-human data for ACCG-2671 confirming its target engagement; we reiterate our Market Outperform rating and maintain our DCF-derived, risk adjusted $110 price target on Structure Therapeutics."

For an analyst ratings summary and ratings history on Structure Therapeutics click here. For more ratings news on Structure Therapeutics click here.

Shares of Structure Therapeutics closed at $40.38 yesterday.

Jefferies Reiterates Buy Rating on Structure Therapeutics (GPCR)

Tue, 08 Sep 2026 09:37:43 -0400

Jefferies analyst Roger Song reiterated a Buy rating and $125.00 price target on Structure Therapeutics (NASDAQ: GPCR).

The analyst comments "Bottom line. We see first small molecule amylin ACCG-2671 data hit our bull case (PREVIEW), including PK/ safety/ GI tolerability/ weight loss, and exceeded our (likely investors') expectations on peptide-like weight loss despite in normal BMI + bone benefit signals. Co plans to test both QD and QW dosing in Ph2a 12W study, and we believe data in 1H27 will be highly valuable as could: 1) validate at least competitive profile as a first-in-class SM oral; 2) increase strategic value as

Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Management

Tue, 08 Sep 2026 08:00:00 -0400

ACCG-2671 (oral small molecule amylin receptor agonist) demonstrated a ~6-day half-life, no serious adverse events, and evidence of target engagement including up to 3.3% body weight loss in Phase 1/2a SAD clinical trial

First participants dosed with ACCG-2671 in the 12-week MAD portion of the Phase 1/2a clinical trial; topline data expected in 1H 2027

Aleniglipron (oral small molecule selective GLP-1 receptor agonist) demonstrated up to 16.2% mean reduction in body weight at 72 weeks with no observed plateau, and improved tolerability with a 2.5 mg starting dose, including less than 5% study-drug discontinuation rates

Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Management

Tue, 08 Sep 2026 08:00:00 -0400

ACCG-2671 (oral small molecule amylin receptor agonist) demonstrated a ~6-day half-life, no serious adverse events, and evidence of target engagement including up to 3.3% body weight loss in Phase 1/2a SAD clinical trial

First participants dosed with ACCG-2671 in the 12-week MAD portion of the Phase 1/2a clinical trial; topline data expected in 1H 2027

Aleniglipron (oral small molecule selective GLP-1 receptor agonist) demonstrated up to 16.2% mean reduction in body weight at 72 weeks with no observed plateau, and improved tolerability with a 2.5 mg starting dose, including less than 5% study-drug discontinuation rates

Structure Therapeutics to Participate in Upcoming Healthcare Investor Conferences

Thu, 03 Sep 2026 07:30:00 -0400

SAN FRANCISCO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced that management will participate in three upcoming healthcare conferences in September:

2026 Cantor Global Healthcare Conference
Date: Thursday, September 10
Format: Fireside chat and 1x1 meetings
Time: 3:55 – 4:25 PM EDT
Location: New York, NY

Morgan Stanley 24^th Annual Global Healthcare Conference
Date: Wednesday, September 16
Format: Fireside chat and 1x1 meetings
Time: 10:45 – 11:20 AM EDT
Location: New

Structure Therapeutics to Participate in Upcoming Healthcare Investor Conferences

Thu, 03 Sep 2026 07:30:00 -0400

SAN FRANCISCO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced that management will participate in three upcoming healthcare conferences in September:

2026 Cantor Global Healthcare Conference
Date: Thursday, September 10
Format: Fireside chat and 1x1 meetings
Time: 3:55 – 4:25 PM EDT
Location: New York, NY

Morgan Stanley 24^th Annual Global Healthcare Conference
Date: Wednesday, September 16
Format: Fireside chat and 1x1 meetings
Time: 10:45 – 11:20 AM EDT
Location: New

Form 4 Structure Therapeutics For: Aug 18 Filed by: Lin Xichen

Wed, 19 Aug 2026 20:23:00 -0400
si-local-file:///var/storage/secattach/20260819/26951602.html

Form 4 Structure Therapeutics For: Aug 18 Filed by: Lin Xichen

Wed, 19 Aug 2026 20:23:00 -0400
si-local-file:///var/storage/secattach/20260819/26951602.html

Form 4 Structure Therapeutics For: Aug 06 Filed by: Berrios John Joseph

Fri, 07 Aug 2026 16:09:00 -0400
si-local-file:///var/storage/secattach/20260807/26891083.html

Form 4 Structure Therapeutics For: Aug 06 Filed by: Berrios John Joseph

Fri, 07 Aug 2026 16:09:00 -0400
si-local-file:///var/storage/secattach/20260807/26891083.html

Form 3 Structure Therapeutics For: Aug 06 Filed by: Berrios John Joseph

Fri, 07 Aug 2026 16:07:00 -0400
si-local-file:///var/storage/secattach/20260807/26891015.html

Form 3 Structure Therapeutics For: Aug 06 Filed by: Berrios John Joseph

Fri, 07 Aug 2026 16:07:00 -0400
si-local-file:///var/storage/secattach/20260807/26891015.html

Structure Therapeutics (GPCR) PT Lowered to $110 at Citizens

Fri, 07 Aug 2026 07:26:04 -0400

Citizens analyst Jonathan Wolleben lowered the price target on Structure Therapeutics (NASDAQ: GPCR) to $110.00 (from $113.00) while maintaining a Market Outperform rating.
The analyst commented, "We continue to view aleniglipron as a potential best-in-class, small-molecule GLP agonist and the start of the Phase 3 ACCOMPLISH program marks an important milestone for the company. We are also looking to additional Phase 2 readouts throughout the rest of the year that should further support the improved tolerability profile of starting at a 2.5 mg dose – which is being utilized in Phase 3. We also note GPCR’s oral amylin candidates are progressing

Structure Therapeutics (GPCR) PT Lowered to $110 at Citizens

Fri, 07 Aug 2026 07:26:04 -0400

Citizens analyst Jonathan Wolleben lowered the price target on Structure Therapeutics (NASDAQ: GPCR) to $110.00 (from $113.00) while maintaining a Market Outperform rating.
The analyst commented, "We continue to view aleniglipron as a potential best-in-class, small-molecule GLP agonist and the start of the Phase 3 ACCOMPLISH program marks an important milestone for the company. We are also looking to additional Phase 2 readouts throughout the rest of the year that should further support the improved tolerability profile of starting at a 2.5 mg dose – which is being utilized in Phase 3. We also note GPCR’s oral amylin candidates are progressing

Form 10-Q Structure Therapeutics For: Jun 30

Thu, 06 Aug 2026 16:29:00 -0400
si-local-file:///var/storage/secattach/20260806/26884663.html

Form 10-Q Structure Therapeutics For: Jun 30

Thu, 06 Aug 2026 16:29:00 -0400
si-local-file:///var/storage/secattach/20260806/26884663.html